Alto Neuroscience, Inc. (NYSE: ANRO) AI-Powered Stock Analysis
See how Alto Neuroscience, Inc. scores across key metrics like financial growth, valuation, and market position on the NYSE, using AI-driven evaluation.
ANRO●NYSE
HealthcareBiotechnology
$27.87
$1.09(4.07%)
U.S. Market opens in 14h 28m
Alto Neuroscience, Inc. (NYSE: ANRO) AI-Powered Stock Analysis
See how Alto Neuroscience, Inc. scores across key metrics like financial growth, valuation, and market position on the NYSE, using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerAlto Neuroscience, Inc. (NYSE: ANRO) Stock Overall Grade
Alto Neuroscience, Inc.'s grade for its NYSE listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Alto Neuroscience, Inc.'s overall NYSE stock rating.
Forecast
AScore
89/100Financial Growth
CScore
40/100Fundamental Growth
CScore
41/100Key Ratios
C+Score
55/100Sector Comparison
BScore
65/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
97/100Analyst Consensus
B+Score
75/100Alto Neuroscience, Inc. (NYSE: ANRO) AI-Powered Stock Analysis
On the NYSE, ANRO demonstrates Good performance with an overall Forecast Score of 89/100 (A), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (41/100, C) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (65/100, B) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), the NYSE-listed stock shows competitive strength. Analyst Consensus (75/100, B+) suggests Moderate divergence in outlook.(NYSE: ANRO) Component Analysis Explained
Understand the key factors behind each Alto Neuroscience, Inc. (NYSE: ANRO) stock grade, including financials, comparisons, and forecasts.